HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 335 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 1.07 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $434,000 | -77.4% | 10,972 | -74.9% | 0.03% | -72.0% |
| Q2 2022 | $1,924,000 | +92.8% | 43,731 | +74.8% | 0.09% | +66.1% |
| Q1 2022 | $998,000 | -36.4% | 25,017 | -35.8% | 0.06% | -3.4% |
| Q4 2021 | $1,568,000 | -26.7% | 38,996 | -25.8% | 0.06% | -47.7% |
| Q3 2021 | $2,138,000 | +87.1% | 52,545 | +108.7% | 0.11% | +126.5% |
| Q2 2021 | $1,143,000 | +35.7% | 25,177 | +24.7% | 0.05% | +4.3% |
| Q1 2021 | $842,000 | +28.2% | 20,193 | +31.2% | 0.05% | -14.5% |
| Q4 2020 | $657,000 | +105.3% | 15,392 | +26.2% | 0.06% | +57.1% |
| Q3 2020 | $320,000 | -21.0% | 12,195 | -53.3% | 0.04% | +40.0% |
| Q3 2019 | $405,000 | +27.4% | 26,100 | +41.1% | 0.02% | -10.7% |
| Q2 2019 | $318,000 | -62.4% | 18,500 | -64.8% | 0.03% | -78.1% |
| Q1 2019 | $845,000 | – | 52,500 | – | 0.13% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |